Acoris & c-LEcta enter into a strategic partnership

Mumbai/Leipzig, August 11, 2009 – Acoris Research Ltd., a wholly owned subsidiary of Hikal Ltd, and c-LEcta, a Germany based industrial biotech company entered into a strategic partnership to develop synthetic routes for chiral compounds. The partnership combines the expertise of Acoris in Process Development and small scale manufacturing, and the unique biocatalysis technologies of c-LEcta.

Acoris Research, based at the International Biotech Park in Pune, India has a state-of-the-art contract research facility and delivers contract research and manufacturing services to innovator companies while c-LEcta, based in Leipzig, Germany is an industrial biotechnology company and holds a patent-protected biotechnology platform for developing new industrial enzymes.

Commenting on this partnership, Dr. M. Struhalla, CEO of c-LEcta said “We are delighted to partner with Acoris in India. Acoris has state-of-the-art facilities and a pool of world class scientific talent to work with us on a broad range of enzymes. c-LEcta’s proprietary screening technology allows for integration of bioconversion steps early in the route scouting process”.

Dr. R. H. Rupp, President of Acoris said “Enzymatic technologies are a valuable extension of the toolbox and innovative value creating procedures for client projects. We are glad to announce our partnership with c-LEcta. The combined synergies of our technical collaboration will further enhance our offerings and would be a significant value addition to our clients”.